Neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans

Free Radical Biology and Medicine

Volumn 97, Issue , 2016, Pages 212-222

  Bessler, Waylan K ^a   Hudson, Farlyn Z ^b   Zhang, Hanfang ^b   Harris, Valerie ^b   Wang, Yusi ^b   Mund, Julie A ^a,c   Downing, Brandon ^a   Ingram, David A ^a   Case, Jamie ^a,c,d   Fulton, David J ^b   Stansfield, Brian K ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SCRIPPS CLINIC   (United States)

Author keywords

Apocynin; Macrophage; Monocyte; NADPHoxidase; Neointima; Neurofibromatosis; Ras; Reactiveoxygenspecies; Smooth musclecell; Superoxide

Indexed keywords

APOCYNIN; CASPASE 3; CD14 ANTIGEN; CD16 ANTIGEN; GLYCOPROTEIN GP 91; NEUROFIBROMIN; P21 ACTIVATED KINASE; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; CYBB PROTEIN, MOUSE; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CAROTID ARTERY INJURY; CAROTID ARTERY LIGATION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOCYTE; MONONUCLEAR CELL; MOUSE; NEOINTIMA; NEUROFIBROMATOSIS TYPE 1; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; SMOOTH MUSCLE CELL; ANIMAL; CAROTID ARTERY OBSTRUCTION; GENETICS; HETEROZYGOTE; MACROPHAGE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CAROTID STENOSIS; CELL PROLIFERATION; DNA DAMAGE; HETEROZYGOTE; HUMANS; MACROPHAGES; MICE; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE 2; NEOINTIMA; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS P21(RAS); REACTIVE OXYGEN SPECIES;

EID: 84974686570     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.06.002     Document Type: Article

References (77)

1. N. Ratner, and S.J. Miller A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor Nat. Rev. Cancer 15 5 2015 290 301
2. J.M. Friedman, J. Arbiser, J.A. Epstein, D.H. Gutmann, S.J. Huot, A.E. Lin, B. McManus, and B.R. Korf Cardiovascular disease in neurofibromatosis 1: report of the NF1 cardiovascular task force Genet. Med. 4 3 2002 105 111
3. A.E. Lin, P.H. Birch, B.R. Korf, R. Tenconi, M. Niimura, M. Poyhonen, K. Armfield Uhas, M. Sigorini, R. Virdis, C. Romano, and et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1 Am. J. Med. Genet. 95 2 2000 108 117
4. G.S. Oderich, T.M. Sullivan, T.C. Bower, P. Gloviczki, D.V. Miller, D. Babovic-Vuksanovic, T.A. Macedo, and A. Stanson Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results J. Vasc. Surg. 46 3 2007 475 484
5. D. Rea, J.F. Brandsema, D. Armstrong, P.C. Parkin, G. deVeber, D. MacGregor, W.J. Logan, and R. Askalan Cerebral arteriopathy in children with neurofibromatosis type 1 Pediatrics 124 3 2009 e476 e483
6. T.L. Rosser, G. Vezina, and R.J. Packer Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1 Neurology 64 3 2005 553 555
7. S.A. Rasmussen, and J.M. Friedman NF1 gene and neurofibromatosis 1 Am. J. Epidemiol. 151 1 2000 33 40
8. E.A. Lasater, F. Li, W.K. Bessler, M.L. Estes, S. Vemula, C.M. Hingtgen, M.C. Dinauer, R. Kapur, S.J. Conway, and D.A. Ingram Jr. Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans J. Clin. Invest. 120 3 2010 859 870
9. E.A. Lasater, W.K. Bessler, L.E. Mead, W.E. Horn, D.W. Clapp, S.J. Conway, D.A. Ingram, and F. Li Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway Hum. Mol. Genet. 17 15 2008 2336 2344
10. B.K. Stansfield, W.K. Bessler, R. Mali, J.A. Mund, B.D. Downing, R. Kapur, and D.A. Ingram Jr. Ras-mek-erk signaling regulates nf1 heterozygous neointima formation Am. J. Pathol. 184 1 2014 79 85
11. B.K. Stansfield, W.K. Bessler, R. Mali, J.A. Mund, B. Downing, F. Li, K.N. Sarchet, M.R. DiStasi, S.J. Conway, R. Kapur, and et al. Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway Hum. Mol. Genet. 22 5 2013 977 988
12. +/- monocytes/macrophages induce neointima formation via CCR2 activation. Hum. Mol. Genet., 2016.
13. D.I. Brown, and K.K. Griendling Regulation of signal transduction by reactive oxygen species in the cardiovascular system Circ. Res. 116 3 2015 531 549
14. E. Ferro, L. Goitre, E. Baldini, S.F. Retta, and L. Trabalzini Ras GTPases are both regulators and effectors of redox agents Methods Mol. Biol. 1120 2014 55 74
15. L. Mitchell, G.A. Hobbs, A. Aghajanian, and S.L. Campbell Redox regulation of Ras and Rho GTPases: mechanism and function Antioxid. Redox Signal. 18 3 2013 250 258
16. P.S. Hole, L. Pearn, A.J. Tonks, P.E. James, A.K. Burnett, R.L. Darley, and A. Tonks Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells Blood 115 6 2010 1238 1246
17. Y. Adachi, Y. Shibai, J. Mitsushita, W.H. Shang, K. Hirose, and T. Kamata Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6 Oncogene 27 36 2008 4921 4932
18. X.J. Li, C.B. Goodwin, S.C. Nabinger, B.M. Richine, Z. Yang, H. Hanenberg, H. Ohnishi, T. Matozaki, G.S. Feng, and R.J. Chan Protein-tyrosine phosphatase Shp2 positively regulates macrophage oxidative burst J. Biol. Chem. 290 7 2015 3894 3909
19. N.Y. Bhatt, T.W. Kelley, V.V. Khramtsov, Y. Wang, G.K. Lam, T.L. Clanton, and C.B. Marsh Macrophage-colony-stimulating factor-induced activation of extracellular-regulated kinase involves phosphatidylinositol 3-kinase and reactive oxygen species in human monocytes J. Immunol. 169 11 2002 6427 6434
20. F. Hannan, I. Ho, J.J. Tong, Y. Zhu, P. Nurnberg, and Y. Zhong Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras Hum. Mol. Genet. 15 7 2006 1087 1098
21. J. Tong, F. Hannan, Y. Zhu, A. Bernards, and Y. Zhong Neurofibromin regulates G protein-stimulated adenylyl cyclase activity Nat. Neurosci. 5 2 2002 95 96
22. J.J. Tong, S.E. Schriner, D. McCleary, B.J. Day, and D.C. Wallace Life extension through neurofibromin mitochondrial regulation and antioxidant therapy for neurofibromatosis-1 in Drosophila melanogaster Nat. Genet. 39 4 2007 476 485
23. D.A. Mayes, T.A. Rizvi, H. Titus-Mitchell, R. Oberst, G.M. Ciraolo, C.V. Vorhees, A.P. Robinson, S.D. Miller, J.A. Cancelas, A.O. Stemmer-Rachamimov, and et al. Nf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculature Cell Rep. 4 6 2013 1197 1212
24. D.A. Ingram, K. Hiatt, A.J. King, L. Fisher, R. Shivakumar, C. Derstine, M.J. Wenning, B. Diaz, J.B. Travers, A. Hood, and et al. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro J. Exp. Med. 194 1 2001 57 69
25. J. Yan, S. Chen, Y. Zhang, X. Li, Y. Li, X. Wu, J. Yuan, A.G. Robling, R. Kapur, R.J. Chan, and et al. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1 Hum. Mol. Genet. 17 7 2008 936 948
26. F. Li, A.M. Munchhof, H.A. White, L.E. Mead, T.R. Krier, A. Fenoglio, S. Chen, X. Wu, S. Cai, F.C. Yang, and et al. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells Hum. Mol. Genet. 15 11 2006 1921 1930
27. A. Panday, M.K. Sahoo, D. Osorio, and S. Batra NADPH oxidases: an overview from structure to innate immunity-associated pathologies Cell. Mol. Immunol. 12 1 2015 5 23
28. G. Berton, M.A. Castaldi, M.A. Cassatella, and W.M. Nauseef Editorial: celebrating the 50th anniversary of the seminal discovery that the phagocyte respiratory burst enzyme is an NADPH oxidase J. Leukoc. Biol. 97 1 2015 1 2
29. K.K. Griendling, D. Sorescu, and M. Ushio-Fukai NAD(P)H oxidase: role in cardiovascular biology and disease Circ. Res. 86 5 2000 494 501
30. D.H. Gutmann, A. Aylsworth, J.C. Carey, B. Korf, J. Marks, R.E. Pyeritz, A. Rubenstein, and D. Viskochil The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2 JAMA: J. Am. Med. Assoc. 278 1 1997 51 57
31. M.C. Yoder, L.E. Mead, D. Prater, T.R. Krier, K.N. Mroueh, F. Li, R. Krasich, C.J. Temm, J.T. Prchal, and D.A. Ingram Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals Blood 109 5 2007 1801 1809
32. A. Azqueta, K.B. Gutzkow, G. Brunborg, and A.R. Collins Towards a more reliable comet assay: optimising agarose concentration, unwinding time and electrophoresis conditions Mutat. Res. 724 1-2 2011 41 45
33. P.F. Li, R. Dietz, and R. von Harsdorf Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells Circulation 96 10 1997 3602 3609
34. T. Ashino, M. Yamamoto, T. Yoshida, and S. Numazawa Redox-sensitive transcription factor Nrf2 regulates vascular smooth muscle cell migration and neointimal hyperplasia Arterioscler. Thromb. Vasc. Biol. 33 4 2013 760 768
35. R.E. Clempus, and K.K. Griendling Reactive oxygen species signaling in vascular smooth muscle cells Cardiovasc. Res. 71 2 2006 216 225
36. A.N. Lyle, and K.K. Griendling Modulation of vascular smooth muscle signaling by reactive oxygen species Physiology 21 2006 269 280
37. S.J. Hamilton, and J.M. Friedman Insights into the pathogenesis of neurofibromatosis 1 vasculopathy Clin. Genet. 58 5 2000 341 344
38. Y. Chen, J. Jiang, H. Miao, X. Chen, X. Sun, and Y. Li Hydrogen-rich saline attenuates vascular smooth muscle cell proliferation and neointimal hyperplasia by inhibiting reactive oxygen species production and inactivating the Ras-ERK1/2-MEK1/2 and Akt pathways Int. J. Mol. Med. 31 3 2013 597 606
39. S.L. Liu, Y.H. Li, G.Y. Shi, S.H. Tang, S.J. Jiang, C.W. Huang, P.Y. Liu, J.S. Hong, and H.L. Wu Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice Cardiovasc. Res. 82 1 2009 161 169
40. S. Altenhofer, K.A. Radermacher, P.W. Kleikers, K. Wingler, and H.H. Schmidt Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement Antioxid. Redox Signa. 23 5 2015 406 427
41. L. Yu, M.T. Quinn, A.R. Cross, and M.C. Dinauer Gp91(phox) is the heme binding subunit of the superoxide-generating NADPH oxidase Proc. Natl. Acad. Sci. USA 95 14 1998 7993 7998
42. S. Heumuller, S. Wind, E. Barbosa-Sicard, H.H. Schmidt, R. Busse, K. Schroder, and R.P. Brandes Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant Hypertension 51 2 2008 211 217
43. R.P. Brandes, N. Weissmann, and K. Schroder Nox family NADPH oxidases: molecular mechanisms of activation Free Radic. Biol. Med. 76 2014 208 226
44. R.P. Brandes, N. Weissmann, and K. Schroder Redox-mediated signal transduction by cardiovascular Nox NADPH oxidases J. Mol. Cell. Cardiol. 73 2014 70 79
45. S.J. Park, B. Sawitzki, L. Kluwe, V.F. Mautner, N. Holtkamp, and A. Kurtz Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors BMC Med. 11 2013 109
46. G.A. Mashour, P.H. Driever, M. Hartmann, S.N. Drissel, T. Zhang, B. Scharf, U. Felderhoff-Muser, S. Sakuma, R.E. Friedrich, R.L. Martuza, and et al. Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1 Clin. Cancer Res. 10 17 2004 5677 5683
47. K. Sullivan, J. El-Hoss, K.G. Quinlan, N. Deo, F. Garton, J.T. Seto, M. Gdalevitch, N. Turner, G.J. Cooney, M. Kolanczyk, and et al. NF1 is a critical regulator of muscle development and metabolism Hum. Mol. Genet. 23 5 2014 1250 1259
48. E.C. O'Brien, W.H. Abdulahad, A. Rutgers, M.G. Huitema, V.P. O'Reilly, A.M. Coughlan, M. Harrington, P. Heeringa, M.A. Little, and F.B. Hickey Intermediate monocytes in ANCA vasculitis: increased surface expression of ANCA autoantigens and IL-1beta secretion in response to anti-MPO antibodies Sci. Rep. 5 11888 2015
49. L. Ziegler-Heitbrock Blood monocytes and their subsets: established features and open questions Front. Immunol. 6 423 2015
50. B.K. Stansfield, and D.A. Ingram Clinical significance of monocyte heterogeneity Clin. Transl. Med. 4 5 2015
51. D. Komatsu, M. Kato, J. Nakayama, S. Miyagawa, and T. Kamata NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression Oncogene 27 34 2008 4724 4732
52. A.Y. Alexandrova, P.B. Kopnin, J.M. Vasiliev, and B.P. Kopnin ROS up-regulation mediates Ras-induced changes of cell morphology and motility Exp. Cell Res. 312 11 2006 2066 2073
53. M.T. Park, M.J. Kim, Y. Suh, R.K. Kim, H. Kim, E.J. Lim, K.C. Yoo, G.H. Lee, Y.H. Kim, S.G. Hwang, and et al. Novel signaling axis for ROS generation during K-Ras-induced cellular transformation Cell Death Differ. 21 8 2014 1185 1197
54. S. Svegliati, R. Cancello, P. Sambo, M. Luchetti, P. Paroncini, G. Orlandini, G. Discepoli, R. Paterno, M. Santillo, C. Cuozzo, and et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts J. Biol. Chem. 280 43 2005 36474 36482
55. R.S. Keshari, A. Verma, M.K. Barthwal, and M. Dikshit Reactive oxygen species-induced activation of ERK and p38 MAPK mediates PMA-induced NETs release from human neutrophils J. Cell. Biochem. 114 3 2013 532 540
56. S. Luanpitpong, P. Chanvorachote, U. Nimmannit, S.S. Leonard, C. Stehlik, L. Wang, and Y. Rojanasakul Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination Biochem. Pharmacol. 83 12 2012 1643 1654
57. F. Molognoni, F.H. de Melo, C.T. da Silva, and M.G. Jasiulionis Ras and Rac1, frequently mutated in melanomas, are activated by superoxide anion, modulate Dnmt1 level and are causally related to melanocyte malignant transformation PLoS One 8 12 2013 e81937
58. I. The, G.E. Hannigan, G.S. Cowley, S. Reginald, Y. Zhong, J.F. Gusella, I.K. Hariharan, and A. Bernards Rescue of a Drosophila NF1) mutant phenotype by protein kinase A Science 276 5313 1997 791 794
59. A.R. Collins Measuring oxidative damage to DNA and its repair with the comet assay Biochim. Biophys. Acta. 1840 2 2014 794 800
60. A. Pemov, C. Park, K.M. Reilly, and D.R. Stewart Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency BMC Genom. 11 194 2010
61. A. Karlsson, J.B. Nixon, and L.C. McPhail Phorbol myristate acetate induces neutrophil NADPH-oxidase activity by two separate signal transduction pathways: dependent or independent of phosphatidylinositol 3-kinase J. Leukoc. Biol. 67 3 2000 396 404
62. J.A. Frost, T.D. Geppert, M.H. Cobb, and J.R. Feramisco A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha-Ras, phorbol 12-myristate 13-acetate, and serum Proc. Natl. Acad. Sci. USA 91 9 1994 3844 3848
63. D. Buscher, R.A. Hipskind, S. Krautwald, T. Reimann, and M. Baccarini Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages Mol. Cell. Biol. 15 1 1995 466 475
64. M.E. Smith, K. van der Maesen, F.P. Somera, and R.A. Sobel Effects of phorbol myristate acetate (PMA) on functions of macrophages and microglia in vitro Neurochem. Res. 23 3 1998 427 434
65. A. Anwar, A.K. Keating, D. Joung, S. Sather, G.K. Kim, K.K. Sawczyn, L. Brandao, P.M. Henson, and D.K. Graham Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress J. Leukoc. Biol. 86 1 2009 73 79
66. K. Winiarska, R. Jarzyna, J.M. Dzik, A.K. Jagielski, M. Grabowski, A. Nowosielska, D. Focht, and B. Sierakowski ERK1/2 pathway is involved in renal gluconeogenesis inhibition under conditions of lowered NADPH oxidase activity Free Radic. Biol. Med. 81 2015 13 21
67. L. Vergori, E. Lauret, A. Gaceb, C. Beauvillain, R. Andriantsitohaina, and M.C. Martinez PPARalpha regulates endothelial progenitor cell maturation and myeloid lineage differentiation through a NADPH oxidase-dependent mechanism in mice Stem Cells 33 4 2015 1292 1303
68. J. Kučera, L. Binó, K. Štefková, J. Jaroš, O. Vašíček, J. Večeřa, L. Kubala, and J. Pacherník Apocynin and diphenyleneiodonium induce oxidative stress and modulate PI3K/Akt and MAPK/Erk activity in mouse embryonic stem cells Oxid. Med. Cell. Longev. 2016 2015
69. S.B. Kritchevsky, T. Shimakawa, G.S. Tell, B. Dennis, M. Carpenter, J.H. Eckfeldt, H. Peacher-Ryan, and G. Heiss Dietary antioxidants and carotid artery wall thickness. The ARIC study. Atherosclerosis risk in communities study Circulation 92 8 1995 2142 2150
70. M. Aviram, M. Rosenblat, D. Gaitini, S. Nitecki, A. Hoffman, L. Dornfeld, N. Volkova, D. Presser, J. Attias, H. Liker, and et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation Clin. Nutr. 23 3 2004 423 433
71. K.K. Griendling, and G.A. FitzGerald Oxidative stress and cardiovascular injury: Part II: animal and human studies Circulation 108 17 2003 2034 2040
72. F. Li, B.D. Downing, L.C. Smiley, J.A. Mund, M.R. Distasi, W.K. Bessler, K.N. Sarchet, D.M. Hinds, L.M. Kamendulis, C.M. Hingtgen, and et al. Neurofibromin-deficient myeloid cells are critical mediators of aneurysm formation in vivo Circulation 129 11 2014 1213 1224
73. A.D. Cox, C.J. Der, and M.R. Philips Targeting RAS membrane association: back to the future for Anti-RAS drug discovery? Clin. Cancer Res. 21 8 2015 1819 1827
74. L.C. Krab, A. de Goede-Bolder, F.K. Aarsen, S.M. Pluijm, M.J. Bouman, J.N. van der Geest, M. Lequin, C.E. Catsman, W.F. Arts, S.A. Kushner, and et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial JAMA: J. Am. Med. Assoc. 300 3 2008 287 294
75. W. Wang, J.S. Nyman, H.E. Moss, G. Gutierrez, G.R. Mundy, X. Yang, and F. Elefteriou Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts J. Bone Miner. Res. 25 7 2010 1658 1667
76. M. Kolanczyk, J. Kuhnisch, N. Kossler, M. Osswald, S. Stumpp, B. Thurisch, U. Kornak, and S. Mundlos Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin BMC Med. 6 21 2008
77. M.T. Acosta, P.G. Kardel, K.S. Walsh, K.N. Rosenbaum, G.A. Gioia, and R.J. Packer Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study Pediatr. Neurol. 45 4 2011 241 245